CV THERAPEUTICS INC. CVTX (NASDAQ)

(PALO ALTO, Calif.)CV Therapeutics Inc. winnowed its loss by 26 percent in the third quarter, the biopharmaceutical company said Thursday, because of improved sales of its angina drug Ranexa and grea...READ MORE

(PALO ALTO, Calif.)The Food and Drug Administration approved Ranexa as a primary treatment for a kind of chest pain, maker CV Therapeutics Inc. said Thursday, adding to its earlier approval of the dr...READ MORE

(PALO ALTO, Calif.)Biotechnology company CV Therapeutics Inc. said Monday the Food and Drug Administration will take longer than expected to review a request to approve its drug Ranexa as an initial ...READ MORE

(PALO ALTO, Calif.)Biotechnology company CV Therapeutics Inc. said Thursday European regulators approved its chronic angina drug Ranexa, which is called Ranolazine outside the U.S.READ MORE

(PALO ALTO, Calif.)Biopharmaceutical company CV Therapeutics Inc. said Tuesday it has received a milestone payment of $10 million from TPG-Axon Capital related to the commercial launch of its stress ...READ MORE

Among the earnings stories for Friday, April 25, from AP Financial News: STOCKHOLM, Sweden (AP) _ Swedish truck maker Volvo AB said Friday that first-quarter profit rose 12 percent...READ MORE

(NEW YORK)CV Therapeutics, the pharmaceutical company said on Tuesday it received an investment of $175 million from TPG-Axon Capital for rights to 50 percent of royalty of the Lexiscan inje...READ MORE